Clinical Trial TitleStudy on the cellular autoimmune mechanisms of narcolepsy.
Clinical Trial Protocol Description:
The purpose of this study is to determine whether narcolepsy patients with cataplexy exhibit an autoimmune response against the peptide orexin, which is depleted in this condition. A blood sample of 30 mL (about 2 tablespoons) will be taken to measure the participant’s cellular immune response against orexin. Subjects will also be tested for a DQB1 allele that is strongly linked to narcolepsy with cataplexy.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are at least 6 years of age.
You will be excluded from the study if any of the following criteria apply to you:
- Have narcolepsy without cataplexy.
- Have a sleep disorder other than narcolepsy.
This is a partial list of inclusion and exclusion criteria.
Clinical Trial Investigator
Igor J. Koralnik, MD
Dom Tucker or Zack Orban
(312) 563-7317 or (312) 563-7304
RUSH University Medical Center
1620 W Harrison St
Chicago, IL 60612